Radiology Department, Hôpital Jean Verdier (APHP), Hôpitaux universitaires Paris-Seine-Saint-Denis, Assistfance Publique Hôpitaux de Paris, Avenue du 14 juillet, 93140, Bondy, France.
Diagnostic and Interventional Radiology Department, CHU Vaudois, Lausanne, Switzerland.
Cardiovasc Intervent Radiol. 2020 Feb;43(2):273-283. doi: 10.1007/s00270-019-02357-9. Epub 2019 Oct 31.
The percutaneous ablation of subcapsular hepatocellular carcinoma (S-HCC) may involve a risk of complications such as hemorrhage and tumor seeding, mainly linked to the direct tumor puncture often inevitable with mono-applicator ablation devices. The purpose of this study was to assess the efficacy and safety of no-touch multi-bipolar radiofrequency ablation (NTMBP-RFA) for the treatment of S-HCC ≤ 5 cm not puncturable via the non-tumorous liver parenchyma.
Between September 2007 and December 2014, 58 consecutive patients (median age: 63 years [46-86], nine females) with 59 S-HCC ≤ 5 cm (median diameter: 25 mm [10-50 mm]), not puncturable via the non-tumorous liver parenchyma, were treated with NTMBP-RFA. Response and follow-up were assessed by CT or MRI. Complications were graded using the Cardiovascular and Interventional Radiological Society of Europe classification. Overall local tumor progression (OLTP)-free survival was assessed using the Kaplan-Meier method. A Cox proportional model evaluated the factors associated with OLTP. Signs of peritoneal or parietal tumor seeding were noted during follow-up imaging studies.
A complete ablation was achieved in 57/58 patients (98.3%) after one (n = 51) or two (n = 6) procedures. Three patients (5.2%) experienced complications (sepsis, cirrhosis decompensation; CIRSE grade 2 or 3). After a median follow-up period of 30.5 months [1-97], no patients had tumor seeding. The 1, 2 and 3-year OLTP-free survival rates were 98%, 94% and 91%, respectively. No factors were associated with OLTP.
NTMBP-RFA is a safe and effective treatment for S-HCC not puncturable via the non-tumorous liver parenchyma.
经皮消融治疗包膜下肝癌(S-HCC)可能会出现出血和肿瘤播散等并发症,这些并发症主要与单器械消融设备难以避免的直接肿瘤穿刺有关。本研究旨在评估不可经非肿瘤性肝实质穿刺的≤5cm S-HCC 应用无接触多极射频消融(NTMBP-RFA)的疗效和安全性。
2007 年 9 月至 2014 年 12 月,58 例连续患者(中位年龄:63 岁[46-86],9 例女性),共 59 个 S-HCC≤5cm(中位直径:25mm[10-50mm]),无法经非肿瘤性肝实质穿刺,接受 NTMBP-RFA 治疗。通过 CT 或 MRI 评估反应和随访。根据心血管和介入放射学会欧洲分类系统(CIRSE)对并发症进行分级。采用 Kaplan-Meier 法评估总局部肿瘤进展(OLTP)无进展生存率。Cox 比例模型评估与 OLTP 相关的因素。在随访影像学研究中注意到腹膜或壁层肿瘤种植的迹象。
57/58 例(98.3%)患者在一次(n=51)或两次(n=6)手术后达到完全消融。3 例(5.2%)患者发生并发症(败血症、肝硬化失代偿;CIRSE 分级 2 或 3)。中位随访 30.5 个月[1-97]后,无患者发生肿瘤种植。1、2、3 年 OLTP 无进展生存率分别为 98%、94%和 91%。无因素与 OLTP 相关。
NTMBP-RFA 是一种安全有效的治疗不可经非肿瘤性肝实质穿刺的 S-HCC 的方法。